Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
About Us
Careers
Conferences
Videos
Webinars
Press Releases
Whitepapers
Advertising
Top Story
Artificial Intelligence
AI-powered endoscope doubles detection of high-risk esophageal lesions
Deep learning has doubled the detection of high-risk lesions during routine endoscopies in a clinical trial of more than 3,000 patients in China.
Featured
Mergers & Acquisitions
Bruker to acquire NanoString for $392.6M
Trends and Finance
DermTech receives delisting warning from Nasdaq
Latest News
Veracyte to share bundle of genomic classifier studies at AUA 2024
April 16, 2024
Nightingale Health to open U.S. lab, collaborate with Englander Institute at Weill Cornell
April 17, 2024
Sponsored
Visit our Molecular Diagnostics Community
April 5, 2024
Babson adds hand-warming to blood testing mini-draws in Texas pharmacies
April 16, 2024
Business Insights
Mergers & Acquisitions
Bruker to acquire NanoString for $392.6M
Trends and Finance
DermTech receives delisting warning from Nasdaq
Collaboration
Nightingale Health to open U.S. lab, collaborate with Englander Institute at Weill Cornell
Trends and Finance
Co-Diagnostics opens manufacturing facility in Utah
Diagnostic Technologies
Artificial Intelligence
AI-powered endoscope doubles detection of high-risk esophageal lesions
Diagnostic Technologies
Veracyte to share bundle of genomic classifier studies at AUA 2024
Regulatory Approval
Roche's breast cancer CDx receives CE Mark
Sequencing
Labcorp expands precision oncology offerings
Diseases
Diagnostic Technologies
Veracyte to share bundle of genomic classifier studies at AUA 2024
Regulatory Approval
Roche, Lilly Alzheimer's blood test granted FDA breakthrough device designation
Prostate Cancer
Lipid enzyme blocker renders prostate cancer cells vulnerable to PARP inhibitors in study
Bladder Cancer
Urine test halves use of invasive procedure to monitor bladder cancer
More from LabPulse.com
OraSure discloses cybersecurity breach
By
LabPulse.com staff writers
OraSure Technology disclosed a cybersecurity incident involving data theft that occurred in late March.
April 15, 2024
Roche, Lilly Alzheimer's blood test granted FDA breakthrough device designation
By
LabPulse.com staff writers
The Alzheimer's blood test developed through a collaboration between Roche and Lilly has been granted a breakthrough device designation by the U.S. Food and Drug Administration (FDA).
April 11, 2024
Lipid enzyme blocker renders prostate cancer cells vulnerable to PARP inhibitors in study
By
Nick Paul Taylor
Blocking lipid synthesis enhanced the effect of PARP inhibitors on prostate cancer in a preclinical study, pointing to a potential way to make the treatments effective in more patients.
April 15, 2024
European Commission approves Illumina's plan to divest Grail
By
LabPulse.com staff writers
The European Commission has approved Illumina's plan to divest multicancer early detection test maker Grail under the European Union Merger Regulation adopted by the EC in October 2023.
April 12, 2024
Roche's breast cancer CDx receives CE Mark
By
LabPulse.com staff writers
Roche has received the CE Mark for the first companion diagnostic (CDx) test to identify patients with HER2-low metastatic breast cancer who may be eligible for treatment with Enhertu.
April 10, 2024
Labcorp expands precision oncology offerings
By
Matt Limb
Laboratory services firm Labcorp has announced the expansion of its precision oncology portfolio, aimed at supporting clinical research and advancing drug development programs.
April 12, 2024
Urine test halves use of invasive procedure to monitor bladder cancer
By
Nick Paul Taylor
A urine test can cut the number of cystoscopies necessary to follow up high-risk bladder cancer patients without increasing the risk of recurrence, a study has found.
April 11, 2024
Researchers tweak TB treatment assay to support global use
By
Nick Paul Taylor
Researchers have developed a tuberculosis (TB) treatment assay that could be a faster, simpler method for monitoring patients.
April 10, 2024
Solvd Health CEO responds to harsh letter addressing FDA, CMS
By
Liz Carey
Solvd Health CEO Dr. Keri Donaldson responded to critics of his company's machine learning classifier clinical laboratory test that uses genotyping to aid healthcare providers in OUD assessments in adults prior to first-time opioid prescriptions.
April 9, 2024
Seaport Therapeutics launches with $100M financing round
By
LabPulse.com staff writers
Clinical-stage biopharmaceutical company Seaport Therapeutics launched with the announcement of the closing of a $100 million oversubscribed series A financing round.
April 9, 2024
Researchers design AI model to generate new antibiotics
By
LabPulse.com staff writers
Researchers have devised an artificial intelligence (AI) model to develop potential new antibiotics which chemists can synthesize in the lab.
April 9, 2024
Johnson & Johnson to acquire Shockwave Medical
By
LabPulse.com staff writers
Johnson & Johnson will acquire Shockwave Medical, expanding Johnson & Johnson MedTech's position in the growing medtech market for cardiovascular intervention.
April 8, 2024